Neogenomics: At A Key Inflection Point In Growth Route (NASDAQ:NEO)

Sabine Hortebusch/iStock via Getty Images

Investment Summary

The investment case for NeoGenomics, Inc. (NASDAQ:NEO) has become increasingly attractive as we work through the first quarter of FY23. Unlike in my previous coverage on NEO [see, in chronological order: herehereherehereQ4 and FY22 numbers


Data: Author, taken from NEO SEC Filings FY18-FY22′


Data: Author, NEO 10-K


Data: NEO Investor Presentation


Data: Seeking Alpha, NEO, see: “Ratings”

Leave a Reply

Your email address will not be published. Required fields are marked *